menu
    • menu
    [{"orgOrder":0,"company":"Otsuka Chemical Co Ltd","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Otsuka Chemical Co Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Otsuka Chemical Co Ltd \/ Otsuka ","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Chemical Co Ltd \/ Otsuka "}]

    Find Clinical Drug Pipeline Developments & Deals by Otsuka Chemical Co Ltd

    Menu

    Otsuka Chemical Co Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Otsuka Chemical Co Ltd

                            Japan arrow
                            Fi Europe 2024
                            Not Confirmed

                            Otsuka Chemical Co Ltd

                            Japan arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacubitril Sodium,Valsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan

                            Details : Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.

                            Brand Name : LCZ696

                            Molecule Type : Small molecule

                            Upfront Cash : $90.0 million

                            March 02, 2020

                            Lead Product(s) : Sacubitril Sodium,Valsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth